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Abstract In patients managed with opioids for chronic
pain, opioid-induced bowel dysfunction—specifically,
opioid-induced constipation (OIC)—is a common side
effect, which has a significant impact on quality of life
(QoL). The most recent developments for management of
OIC are opioid antagonists, including naloxone, a com-
petitive antagonist of peripheral opioid receptors that
reverses opioid-induced peripheral gastrointestinal (GI)
effects. A prolonged-release formulation of naloxone is
available in combination with oxycodone (OXN PR). To
review the specific role of OXN PR in the management of
chronic pain and OIC and its impact on QoL and healthcare
costs, a review of available relevant literature was con-
ducted. Healthcare costs can be up to ten times higher for
patients with GI events than for those without. Assessment
of QoL in patients with OIC is essential, and multiple tools
for its evaluation are available. The Bowel Function Index
(BFI), a tool that was specifically developed and validated
to measure bowel function in patients with OIC, can be an
indication of QoL. In patients with moderate-to-severe
chronic pain, randomized trials have demonstrated that
OXN PR has equal analgesic efficacy and safety, but
results in improved bowel function, compared with
prolonged-release oxycodone (Oxy PR) alone. In conclu-
sion, randomized studies using the BFI, as well as real-
world clinical practice observations, have demonstrated
improved QoL for patients taking OXN PR. This combi-
nation should allow more patients to benefit from the
analgesic efficacy of opioid therapy and should minimize
the side effects of constipation that correspond to
improvements in QoL and healthcare offsets.
Key Points
Opioid induced constipation is a medical condition
that causes a substantial burden to the patient and the
healthcare system.
In clinical studies, oxycodone/naloxone has been
shown to improve bowel function and is estimated to
be cost-effective according to health economic
models.
1 Introduction
Chronic pain is a common and disabling condition, which
can significantly affect quality of life (QoL) [1–5]. A
variety of definitions may be used to define chronic pain;
the International Association for the Study of Pain defines
it as pain without apparent biological value that has per-
sisted beyond the normal tissue healing time (usually taken
to be 3 months) [6]. In a large-scale survey of chronic pain
(defined as pain lasting[6 months with an intensity of C5
on a 1–10 scale) across 15 European countries plus Israel,
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prevalence rates of 12–30 % were reported [2]. Prevalence
rates, however, vary widely between studies because of
differences in population characteristics, sampling methods
and the criteria used to define chronic pain. Pain is a par-
ticular concern for cancer patients and has a significant
impact on their QoL [7]. Up to 70 % of patients with
advanced cancer have been reported to experience chronic
pain [8, 9].
Chronic pain can stem from a variety of underlying
conditions, which may be musculoskeletal, neuropathic,
ischaemic or cancer related [2, 10], and may be seen as a
biopsychosocial phenomenon in which pain interacts with
psychosocial factors [11]. Chronic pain is also strongly
associated with development of comorbidities, including
depression and anxiety, impaired sleep and alterations in
immune function [5, 12–15].
Management strategies for chronic pain are multimodal,
with the aim of reducing pain and maximizing QoL [11,
16]. Non-pharmacotherapeutic management may include
physical and psychological interventions [16]. The major
pharmacological agents currently used to treat chronic
pain include non-opioid analgesics (e.g. paracetamol and
non-steroidal anti-inflammatory drugs, including cycloox-
ygenase-2 inhibitors) and opioids. In addition, atypical
analgesics, including antidepressants and anticonvulsants,
may be used. Pain intensity generally guides the process of
analgesic choice and, in many cases, high-potency drugs
are the first choice of treatment [16, 17]. For cancer pain, a
stepwise approach to pharmacotherapy is generally
advised on the World Health Organization (WHO)
sequential three-step analgesic ladder from non-opioids to
weak opioids, followed by strong opioids [17]. Opioids,
however, are the mainstay and sometimes the first-line
option for pain relief in cancer pain, as they offer the most
effective analgesic therapy [7, 18, 19]. Recent clinical
practice guidelines from the European Society for Medical
Oncology and the European Association for Palliative
Care (EAPC) state that low doses of morphine, oxycodone
or a oxycodone–naloxone combination can be used as step
II on the WHO ladder [7, 20]. Several medical societies
have endorsed the use of opioids for non-cancer pain as a
legitimate medical practice and have published guidelines
for its safe use [21–23]. The value of opioid therapy,
however, must be confirmed for each patient [24]. Mor-
phine is generally the opioid of choice for the treatment of
moderate-to-severe chronic pain [7, 20]. Nonetheless, in a
systematic review for an update of the EAPC guidelines,
oxycodone was shown to be as effective as morphine and
hydromorphone for cancer pain in terms of analgesia and
is one of the most commonly used strong opioids in
Europe [7, 25].
Maximizing QoL is particularly important in individuals
with chronic pain, who may already suffer reduced QoL
because of their pain [26]. Several variables affect QoL,
one of which is pharmacotherapy-related side effects.
Despite the effectiveness of opioids, side effects compro-
mise their therapeutic potential. Side effects may include
nausea, central nervous system events such as confusion
and hallucinations, pruritus and, particularly, opioid-
induced bowel dysfunction (OIBD). OIBD includes a
spectrum of symptoms, the primary one being opioid-
induced constipation (OIC) [27–29]. With long-term use,
many side effects associated with opioid therapy may
subside because of tolerance; however, OIC often lingers
and can significantly affect QoL [2, 28]. Optimal man-
agement of chronic pain with opioids requires a careful
balance between efficacy and tolerability to ensure that
QoL is maintained. One approach to overcome the gas-
trointestinal (GI) side effects of opioids is the use of opioid
antagonists, such as naloxone, naloxegol, methylnaltrexone
and alvimopan [27, 30]. Co-administration of oxycodone (a
semi-synthetic opioid analgesic) with the opioid antagonist
naloxone (OXN) has been demonstrated to counteract the
GI side effects of the analgesic [31–33]. When adminis-
tered orally, naloxone has low systemic bioavailability
(\2 %) and antagonizes peripheral opioid receptors in the
GI tract with little impact on centrally acting opioid anal-
gesia [34]. In this review, we focus on the specific role of
OXN in the management of chronic pain and OIC, and its
impact on QoL and healthcare costs.
2 Opioid-Induced Bowel Dysfunction and Opioid-
Induced Constipation
The GI tract plays a key role in the development of opioid-
related adverse effects, as the main opioid receptors are
widely distributed in the gut. Activation of GI opioid
receptors by exogenous opioids disrupts GI motility and
secretion, thereby inhibiting normal bowel function [35].
The primary adverse effects of opioids frequently lead to
secondary complications, including a constellation of signs
and symptoms known as OIBD. OIBD comprises consti-
pation, anorexia, nausea and vomiting, gastro-oesophageal
reflux, delayed digestion, abdominal pain, flatulence,
bloating, hard stools, straining during bowel movement and
incomplete evacuation. In some cases, it may lead to more
serious complications such as bowel faecal impaction with
overflow diarrhoea and faecal incontinence, pseudo-
obstruction (which may cause anorexia, nausea and vom-
iting), disturbance of drug absorption, urine retention and
urine incontinence. These symptoms further the impact on
patients’ health [35–37] (Fig. 1).
OIC can have a particularly significant impact on
patients’ lives [37, 38]. Estimates of the prevalence of
constipation adverse effects in patients taking opioids
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varies because of variations in patient populations, differ-
ences in administration route, dose and type of the various
opioids available [29, 39, 40]. In patients with chronic non-
cancer pain, prevalence rates of up to 90 % have been
reported [29, 41]. In patients with cancer, a large series of
US hospice studies reported prevalence rates of 40–63 %
[42]. In patients taking opioids, constipation has a serious
impact on QoL and may be even more distressing for the
patient than the pain itself [26, 43–45]. In a large interna-
tional survey of patients taking opioids for [6 months,
those suffering constipation were more likely to visit
physicians, miss work and feel that their performance at
work and their ability to undertake daily activities was
impaired, compared with patients without constipation
[46]. Some patients may even discontinue opioid therapy
because of symptoms of constipation [47]. For these rea-
sons, effective pharmacological therapy for OIC is con-
sidered to be an unmet need [48].
Bowel dysfunction in patients with OIC, however, is not
caused exclusively by the opioid medication. Factors such
as pain, medications other than opioids, diet and underlying
disease factors play an important role in the complex
pathophysiology of constipation [26].
3 Quality of Life in Patients with Chronic Pain
QoL is one of the most important patient-centred outcomes
of medical care [49, 50] and is a multidimensional
parameter for which coverage may be categorized within
five dimensions: physical wellbeing, material wellbeing,
social wellbeing, emotional wellbeing, and development
and activity [51]. In some individuals, such as older
patients with long-term illness and those with no possible
cure, QoL can be the only achievable outcome [50]. In a
comprehensive international study covering eight coun-
tries, it was demonstrated that suffering from a chronic
condition substantially reduces QoL [52].
Chronic pain is a condition that has a significant impact
on the social and working lives of sufferers and may even
lead to social isolation. A large pan-European study
involving [45,000 individuals suffering chronic pain
reported that 21 % were diagnosed with depression due to
their pain, 61 % were less able or unable to work outside
the home, 19 % had lost their job and 13 % had changed
jobs because of their pain [2]. A total of 60 % of these
individuals had visited their doctor for their pain 2–9 times
in the previous 6 months [2].
In addition to the reduced QoL due to pain, sufferers of
moderate-to-severe pain treated with opioid medication often
bear the additional burden of adverse effects of their pain
medication, particularly OIC [28, 35]. Assessment of QoL in
patients with OIC can assist therapeutic choices, and numer-
ous assessment tools are available to assist in evaluation.
3.1 Tools to Measure Quality of Life in Patients
with Chronic Pain and Constipation
Numerous tools are available to measure QoL in
















Fig. 1 Primary and secondary





QoL and Healthcare Resource in Patients Receiving Opioids for Chronic Pain 3
tools can be general QoL measures that are designed to
evaluate the effects of interventions or can be utility
measures designed to evaluate judgements of health
outcomes. A selection of QoL tools are listed in
Table 1 [53].
3.2 Gastrointestinal-Specific Tools to Measure Quality
of Life in Patients with Constipation
Several tools are available to measure GI symptoms in
patients with constipation (Table 1). These include GI-
specific tools for measuring constipation, including the
Gastrointestinal Symptom Rating Scale [54], the Elderly
Bowel Symptom Questionnaire [55] and the Patient
Assessment of Constipation Symptoms (PAC-SYM)
Questionnaire [56]. The Patient Assessment of Consti-
pation Quality of Life (PAC-QoL) was designed to
include specific QoL outcomes for constipation; was
developed to address the need for a standardized,
patient-reported outcomes measure to evaluate consti-
pation over time; and includes specific QoL-related
measures [57].
3.3 The Bowel Function Index: a Specific Validated
Tool to Measure Bowel Function in Patients
with Opioid-Induced Constipation
The Bowel Function Index (BFI1) is a validated, clinician-
administered, patient-reported, three-item questionnaire
(ease of defecation, feeling of incomplete evacuation and
patient personal judgment of constipation) designed to
evaluate OIC in cancer and non-cancer chronic pain
patients [58–62]. Although not a direct measure of QoL,
the BFI has been shown to be statistically correlated
(r = 0.571; p \ 0.0001) with the Knowles–Eccersley–
Scott symptom score and matches up with PAC-QoL and,
to a lesser extent, with the Medical Outcomes Study
12-Item Short-Form (SF-12) generic QoL questionnaire
[63–65].
1 The BFI is owned by Mundipharma Laboratories GmbH, Switzer-
land (2002); the BFI is the subject of a European Patent Application
(Publication No. EP 1,860,988) and corresponding patents and patent
applications in other countries.
Table 1 Example instruments and tools available for measurement of quality of life in patients with pain and constipation
General health-related measures
Medical Outcomes Study 36-Item Short-Form (SF-36) [93]
Medical Outcomes Study 12-Item Short-Form (SF-12) [94]
Nottingham Health Profile [95]
World Health Organization Quality of Life (WHOQOL) pain subscale [96]
Utility measuresa
EuroQoL [97]
Health Utilities Index (HUI) [98]
Cancer pain-specific tools
Functional Living Index-Cancer (FLIC) [99]
Functional Assessment of Cancer Therapy-General (FACT-G) [100]
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ) [101]b
Gastrointestinal-specific tools for constipation
Gastrointestinal Symptom Rating Scale (GSRS) [54]
Elderly Bowel Symptom Questionnaire (EBSQ) [55]
Patient Assessment of Constipation Symptoms (PAC-SYM) [56]c
Specific quality of life for constipation
Patient Assessment of Constipation Quality of Life (PAC-QoL) [57]d
Opioid-induced constipation-specific tools
Bowel Function Index (BFI) [58]e
a SF-36 may be used as a utility measure
b Developed for use in international clinical trials
c A 12-item self-report instrument divided into abdominal, rectal and stool domains designed to assess symptom frequency and severity, and
validated for use in patients with opioid-induced constipation
d Includes four subscales: worries and concerns, physical discomfort, psychosocial discomfort and satisfaction
e The BFI is owned by Mundipharma Laboratories GmbH, Switzerland (2002); the BFI is the subject of a European Patent Application
(Publication No. EP 1,860,988) and corresponding patents and patent applications in other countries
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3.4 Generic Quality-of-Life Measures
Generic QoL measures are becoming increasingly popular
with health policy makers. One advantage of generic
measures is that they are non-disease specific, so they allow
the policy maker to compare the impact of therapies rela-
tive to therapies in another disease area. These measures
are commonly applied in resource allocation decisions as
policy makers are allocating budgets across multiple and
diverse disease areas. The Medical Outcomes Study
36-Item Short-Form Health Survey (SF-36) is one of the
most widely used generic QoL measures and has been used
in articles describing more than 200 diseases and condi-
tions [66, 67]. One special type of QoL measure is the
utility value, which is implied in health economic models
based on a cost-utility analysis [68, 69]. Utility score health
is usually measured between 0 and 1, where perfect health
is given a score of 1 (although, in extreme cases, the score
can go below 0, which is classified as ‘worse than death’).
There have been a number of utility studies showing the
reduction in QoL due to constipation. One study in patients
with a severe non-curable disease and relatively short life
expectancy treated with opioids found that QoL, as mea-
sured by the EuroQoL five-dimension questionnaire (EQ-
5D), for those without advanced illness who were not
constipated, was much higher (score 0.65) than the score
for those who were constipated (score 0.31) [44]. In
another study in patients with chronic functional consti-
pation, a cost-utility model used to define health status in
terms of the number of quality-adjusted life years (QALYs)
demonstrated a 1 % improvement in health gain for one
laxative over another [70].
4 Economic Burden of Constipation
The economic burden of constipation is vast in terms of
both direct and indirect costs [26, 71]. Constipation-asso-
ciated direct costs include physician visits, hospitalization,
procedures and medications. Indirect costs include self-
medication, lost earnings, restricted activity and costs of
caregivers [26]. In studies conducted in the USA in patients
receiving opioid treatment, direct costs have been demon-
strated to be significantly higher in patients reporting GI
events and constipation than in those not reporting such
events [72, 73]. In an analysis of the costs of medical and
pharmacy claims in patients receiving a new prescription
for oral, short-acting opioid treatment, adjusted mean
healthcare costs per patient during the 90 days after the
opioid therapy were more than ten times higher for patients
experiencing GI events than for those without GI events
(US$40,133 versus US$3,981) [72]. A study conducted in
Sweden in patients treated with strong opioids demonstrated
that total (direct and indirect) costs are particularly high in
patients with severe constipation, reaching €1,525 per
patient per month, compared with €1,034 for patients with
no constipation (Fig. 2) [74]. In cancer patients on opioid
therapy, costs associated with constipation were found to be
especially significant, with increases in total costs of 109 %
for patients who had constipation, compared with those who
did not [71]. Patients with constipation had significantly
higher rates of concurrent use of C2 opioids, opioid dis-
continuation, opioid switching, nausea with vomiting, and
respiratory depression than those without constipation.
Patients with constipation also received more in-patient,
hospice, home health, laboratory, other outpatient, emer-
gency, office visit and nursing home care [71]. Resource
utilization associated with the diagnosis and management of
constipation is a significant cost driver, and constipation
prevention programmes can lead to substantial cost savings
[26].
5 Strategies for the Management of Opioid-Induced
Constipation
Strategies for managing OIC include rotation or reduction
in the dose of the opioid and management of OIC symp-
toms [75]. There are currently two main strategies for the
management of OIC symptoms: the use of laxatives and
treatment with opioid antagonists.
5.1 Laxatives
Laxatives are the most common therapeutic strategy for
OIC [76]. Conventional laxatives either act by affecting
osmotic condition, stimulate bowel action or have emolli-
ent properties. Inhibition of small-intestinal motility is a
prominent feature of opioids and is probably one of the
reasons why laxatives (which act predominantly on the
colon) do not have a satisfactory effect on the majority of
patients with OIC [40]. In addition, laxatives have the
potential for over-use and dependency, and are associated
with adverse effects such as dehydration, bloating and
dermatitis [29, 37]. Despite the wide availability of dif-
ferent laxative types, OIC persists in many patients. In a
multinational survey (PROBE 1), 45 % of patients
receiving opioids and laxatives reported fewer than three
bowel movements per week, 81 % of patients reported
constipation and 58 % reported straining to pass a bowel
movement [40]. In another study, 54 % of patients did not
achieve a desired result with laxatives even half of the
time. Despite the fact that OIC is usually treated with
laxatives, there is insufficient clinical evidence that laxa-
tives are efficacious in this indication [77]. In addition, it
appears that laxatives are often not prescribed, even when
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they are indicated. In an audit of clinical practice in
Scotland, 98 % of opioid prescriptions for patients needing
an opioid were for the opioid alone [78].
5.2 Opioid Antagonists
Opioid antagonists aim to counteract the constipation
effects of opioids by antagonizing the peripheral opioid
receptors in the GI tract, while avoiding an impact on
centrally acting opioid analgesia [79, 80]. The main chal-
lenge with opioid antagonists is to inhibit peripheral
actions without affecting their central action, which may
lead to opiate withdrawal symptoms or reversal of the
analgesic effect [79]. Several single-entity opioid antago-
nists, including peripherally acting mu-opioid receptor
antagonists (PAMORAs), are available and in develop-
ment. These include methylnaltrexone, naloxegol and
alvimopan [81]. Methylnaltrexone, which is administered
as an emergency-relief subcutaneous injection when tra-
ditional oral laxatives fail, provides a bowel movement in
approximately 50–60 % of patients but is approved only
for palliative care in patients with advanced illness [75,
82]. Alvimopan, which is approved by the US Food and
Drug Administration (FDA) and is indicated to accelerate
the time to upper and lower GI recovery following sur-
geries that include partial bowel resection with primary
anastomosis, has also been shown to increase spontaneous
bowel movements, but cardiovascular safety concerns have
hindered development of this agent [81]. Naloxegol has
been recently approved by the FDA as an add-on to
existing pain therapy and has shown efficacy for increasing
bowel movements [81]. Oral formulations such as nal-
oxegol and alvimopan provide obvious advantages over
methylnaltrexone in terms of patient acceptance and QoL.
However, these single-entity agents need to be combined
with analgesic agents and therefore carry an intrinsic risk
of lower patient compliance. Unfortunately, as yet, there
are no directly comparative published data for these
PAMORAs, but individual efficacy and safety analyses
have been reviewed in several publications elsewhere [30,
81, 83, 84].
Naloxone is a competitive antagonist of peripheral
opioid receptors with low systemic bioavailability and
therefore has little impact on centrally acting opioid anal-
gesia [34]. Naloxone, as part of a prolonged-release (PR)
combination, reverses opioid-induced peripheral GI effects
[85]. In patients with moderate-to-severe chronic pain,
phase II and phase III randomized trials have demonstrated
that combination PR oxycodone/naloxone (OXN PR) has
equal analgesic efficacy and safety, but with improved
bowel function, compared with oxycodone alone [31–33,
86, 87]. The beneficial effects of OXN PR, compared with
oxycodone, have also been demonstrated over the long
term (\52 weeks) [88].
5.3 Quality-of-Life Benefits of Oxycodone/Naloxone
In the trials evaluating OXN PR, bowel function and QoL
were investigated using the BFI and other tools (Table 2).
In the three phase III trials, conducted mainly in patients
with moderate-to-severe non-malignant pain, significant
improvements in the BFI were seen in patients taking OXN
PR versus those taking oxycodone PR (Oxy PR) [31–33]
(Table 2). These improvements were generally seen after
just 1 week of treatment and continued throughout the
trials [31–33]. Significant and clinically relevant
improvements in symptoms, using PAC-SYM and the
Patient Assessment of Opioid-Induced Constipation, were
also demonstrated [31–33]. The improvements in bowel
function were confirmed in a pooled analysis of the phase
III trials, in which significant improvements were demon-
strated in the BFI for patients receiving OXN PR, com-
pared with those receiving Oxy PR [87]. Statistically




















No constipation = 419
patient months
Mild constipation = 302
patient months

































Severe constipation = 135
patient months
Fig. 2 Mean cost per patient
per month for opioid-treated
patients with and without
constipation [74]
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were observed at week 1 and at every subsequent time
point during the study (-15.1; 95 % CI -17.3 to -13.0;
p \ 0.0001 versus baseline) (Fig. 3) [87]. Similar signifi-
cant improvements in QoL in terms of the BFI were
demonstrated in a randomized phase II study in patients
with severe chronic pain [86]. A 52-week extension study,
in which patients were maintained on OXN PR or switched
from Oxy PR to OXN PR, demonstrated that these
improvements in the BFI are maintained over the long term
[88]. In an evaluation of OXN PR, using the generic QoL
tool SF-36, significant improvements were seen in social
functioning (p = 0.012), vitality (p = 0.010) and the
general health subscale (p = 0.039) at week 12 [89].
In real-world clinical practice, a large non-interventional
study reported improvements in QoL for patients taking
OXN PR [90]. In this German study involving 7,836
individuals with severe chronic pain of various aetiologies
treated with OXN PR, significant reductions in the BFI
were seen both in opioid-naı¨ve and opioid pre-treated
patients [90]. QoL, as measured by the Short-Form Brief
Pain Inventory (BPI-SF), demonstrated an improvement of
43 % in mean overall QoL (in 2,023 individuals) after just
4 weeks of treatment [90].
5.4 Health Economic Benefits of Oxycodone/Naloxone
A UK comparison of the cost effectiveness of OXN PR
versus Oxy PR, using a cost-utility model combining the
costs of pain therapy, laxatives and other resources to
manage constipated patients with moderate-to-severe non-
malignant pain, demonstrated a QoL gain with OXN PR
versus Oxy PR [89]. The incremental gain in QALYs was
based on the SF-36 results mapped to EQ-5D and implied
that patients treated with OXN PR in real-world clinical
practice will experience a QoL gain. Treatment costs were
slightly higher for OXN PR, but this was offset by
increased QALY gains. The ratio of incremental cost to
incremental QALY gain was substantially below com-
monly applied decision thresholds in the UK, suggesting
that OXN PR is cost effective and should be adopted in the
health system [89]. In some scenarios, total cost savings to
the health system have been demonstrated. In a German
study in which patients received OXN PR or other strong
(WHO step III) opioids at 6 months, direct treatment costs
were lower in the OXN PR cohort, and there was a QALY
gain, compared with the cohort taking other strong opioids
[91]. Similar results were seen in a Spanish study in
patients with chronic severe pain and OIC, in which an
incremental cost-effectiveness ratio far below the effi-
ciency threshold commonly cited in Spain was demon-
strated [92].
6 Conclusions
Management of chronic pain is challenging, and unmet
needs remain. Traditional opioids are often the treatment of
choice in moderate and severe pain, but their use is often
compromised by side effects; in particular, OIBD can
substantially reduce QoL. Most treatments for OIBD are
not very effective and are not mechanism based. OXN is
one of the first therapies to act directly on the mechanism
of OIBD and has been shown to be an effective treatment
for this (to date, unmet) need.
The BFI is a specific validated measurement tool that
can assist in the evaluation of bowel function in patients
with OIBD, and specifically with OIC. Treatment of
patients with moderate-to-severe pain with OXN PR has
been demonstrated to significantly improve QoL. Use of
OXN PR should allow more patients to benefit from the
analgesic efficacy of opioid therapy and should minimize
the side effects of constipation, with a corresponding
improvement in QoL. Health economic analysis has shown
OXN PR to be below commonly applied thresholds, with
some cost offsets because of fewer resources being
required to treat the constipation.
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Fig. 3 Mean Bowel Function Index score over time in patients
treated with prolonged-release (PR) oxycodone/naloxone and oxyco-
done PR (pooled analysis of two randomized phase III trials) [87]
8 B. Morlion et al.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and the source are credited.
References
1. Blyth FM, et al. Chronic pain in Australia: a prevalence study.
Pain. 2001;89(2–3):127–34.
2. Breivik H, et al. Survey of chronic pain in Europe: prevalence,
impact on daily life, and treatment. Eur J Pain. 2006;10(4):
287–333.
3. Johannes CB, et al. The prevalence of chronic pain in United
States adults: results of an Internet-based survey. J Pain.
2010;11(11):1230–9.
4. Toblin RL, et al. A population-based survey of chronic pain and
its treatment with prescription drugs. Pain. 2011;152(6):
1249–55.
5. Vetter TR. A primer on health-related quality of life in chronic
pain medicine. Anesth Analg. 2007;104(3):703–18.
6. Pain., I.A.f.t.S.o., Pain, 1986;Suppl 3:S1–S225.
7. Ripamonti CI, et al. Management of cancer pain: ESMO Clin-
ical Practice Guidelines. Ann Oncol. 2012;23(Suppl 7):7139–54.
8. Colvin L, Forbes K, Fallon M. Difficult pain. BMJ.
2006;332(7549):1081–3.
9. Breivik H, et al. Cancer-related pain: a pan-European survey of
prevalence, treatment, and patient attitudes. Ann Oncol.
2009;20(8):1420–33.
10. Apkarian AV, Baliki MN, Geha PY. Towards a theory of
chronic pain. Prog Neurobiol. 2009;87(2):81–97.
11. Gatchel RJ, et al. The biopsychosocial approach to chronic pain:
scientific advances and future directions. Psychol Bull.
2007;133(4):581–624.
12. Ohayon MM, Schatzberg AF. Using chronic pain to predict
depressive morbidity in the general population. Arch Gen Psy-
chiatry. 2003;60(1):39–47.
13. Bair MJ, et al. Depression and pain comorbidity: a literature
review. Arch Intern Med. 2003;163(20):2433–45.
14. Nicholson B, Verma S. Comorbidities in chronic neuropathic
pain. Pain Med. 2004;5(Suppl 1):S9–27.
15. Marchand F, Perretti M, McMahon SB. Role of the immune
system in chronic pain. Nat Rev Neurosci. 2005;6(7):521–32.
16. Morlion B. Chronic low back pain: pharmacological, interven-
tional and surgical strategies. Nat Rev Neurol. 2013;9(8):462–73.
17. Kroenke K, Krebs EE, Bair MJ. Pharmacotherapy of chronic
pain: a synthesis of recommendations from systematic reviews.
Gen Hosp Psychiatry. 2009;31(3):206–19.
18. Colson J, et al. A systematic review of observational studies on
the effectiveness of opioid therapy for cancer pain. Pain Phy-
sician. 2011;14(2):E85–102.
19. Manchikanti L, et al. Effectiveness of long-term opioid therapy
for chronic non-cancer pain. Pain Physician. 2011;14(2):
E133–56.
20. Caraceni A, et al. Use of opioid analgesics in the treatment of
cancer pain: evidence-based recommendations from the EAPC.
Lancet Oncol. 2012;13(2):e58–68.
21. de Leon-Casasola OA. Opioids for chronic pain: new evidence,
new strategies, safe prescribing. Am J Med. 2013;126(3 Suppl
1):S3–11.
22. Practice guidelines for chronic pain management: an updated
report by the American Society of Anesthesiologists Task Force
on Chronic Pain Management and the American Society
of Regional Anesthesia and Pain Medicine. Anesthesiology,
2010;112(4):810–33.
23. Franklin GM. Opioids for chronic noncancer pain: a position
paper of the American Academy of Neurology. Neurology.
2014;83(14):1277–84.
24. Baldini A, Von Korff M, Lin EH. A review of potential adverse
effects of long-term opioid therapy: a practitioner’s guide. Prim
Care Companion CNS Disord. 2012. 14(3).
25. Caraceni A, Pigni A, Brunelli C. Is oral morphine still the first
choice opioid for moderate to severe cancer pain? A systematic
review within the European Palliative Care Research Collabo-
rative guidelines project. Palliat Med. 2011;25(5):402–9.
26. Dennison C, et al. The health-related quality of life and
economic burden of constipation. Pharmacoeconomics. 2005;
23(5):461–76.
27. Holzer P. Opioid antagonists for prevention and treatment of
opioid-induced gastrointestinal effects. Curr Opin Anaesthesiol.
2010;23(5):616–22.
28. Holzer P, et al. Opioid-induced bowel dysfunction in cancer-
related pain: causes, consequences, and a novel approach for its
management. J Opioid Manag. 2009;5(3):145–51.
29. Panchal SJ, Muller-Schwefe P, Wurzelmann JI. Opioid-induced
bowel dysfunction: prevalence, pathophysiology and burden. Int
J Clin Pract. 2007;61(7):1181–7.
30. Chey WD, et al. Naloxegol for opioid-induced constipation in
patients with noncancer pain. N Engl J Med. 2014;370(25):
2387–96.
31. Lowenstein O, et al. Combined prolonged-release oxycodone
and naloxone improves bowel function in patients receiving
opioids for moderate-to-severe non-malignant chronic pain: a
randomised controlled trial. Expert Opin Pharmacother. 2009;
10(4):531–43.
32. Vondrackova D, et al. Analgesic efficacy and safety of oxyco-
done in combination with naloxone as prolonged release tablets
in patients with moderate to severe chronic pain. J Pain.
2008;9(12):1144–54.
33. Simpson K, et al. Fixed-ratio combination oxycodone/naloxone
compared with oxycodone alone for the relief of opioid-induced
constipation in moderate-to-severe noncancer pain. Curr Med
Res Opin. 2008;24(12):3503–12.
34. Smith K, et al. Low absolute bioavailability of oral naloxone in
healthy subjects. Int J Clin Pharmacol Ther. 2012;50(5):360–7.
35. Mehendale SR, Yuan CS. Opioid-induced gastrointestinal dys-
function. Dig Dis. 2006;24(1–2):105–12.
36. Leppert W. Are we able to manage effectively opioid-induced
bowel dysfunction? J Autacoids. 2012(1):1000e113.
37. Pappagallo M. Incidence, prevalence, and management of opi-
oid bowel dysfunction. Am J Surg. 2001;182(5A Suppl):11S–
8S.
38. Wald A, et al. The burden of constipation on quality of life:
results of a multinational survey. Aliment Pharmacol Ther.
2007;26(2):227–36.
39. Rosti G, et al. Opioid-related bowel dysfunction: prevalence and
identification of predictive factors in a large sample of Italian
patients on chronic treatment. Eur Rev Med Pharmacol Sci.
2010;14(12):1045–50.
40. Bell TJ, et al. The prevalence, severity, and impact of opioid-
induced bowel dysfunction: results of a US and European
Patient Survey (PROBE 1). Pain Med. 2009;10(1):35–42.
41. Allan L, et al. Randomised crossover trial of transdermal fen-
tanyl and sustained release oral morphine for treating chronic
non-cancer pain. BMJ. 2001;322(7295):1154–8.
42. McMillan SC. Assessing and managing opiate-induced consti-
pation in adults with cancer. Cancer Control. 2004;11(3
Suppl):3–9.
QoL and Healthcare Resource in Patients Receiving Opioids for Chronic Pain 9
43. Fallon MT, Hanks GW. Morphine, constipation and perfor-
mance status in advanced cancer patients. Palliat Med.
1999;13(2):159–60.
44. Penning-van Beest FJ, et al. Quality of life in relation to con-
stipation among opioid users. J Med Econ. 2010;13(1):129–35.
45. McMillan SC, Small BJ. Symptom distress and quality of life in
patients with cancer newly admitted to hospice home care.
Oncol Nurs Forum. 2002;29(10):1421–8.
46. Bell T, Annunziata K, Leslie JB. Opioid-induced constipation
negatively impacts pain management, productivity, and health-
related quality of life: findings from the National Health and
Wellness Survey. J Opioid Manag. 2009;5(3):137–44.
47. Kurz A, Sessler DI. Opioid-induced bowel dysfunction: patho-
physiology and potential new therapies. Drugs. 2003;63(7):
649–71.
48. Ketwaroo GA, Cheng V, Lembo A. Opioid-induced bowel
dysfunction. Curr Gastroenterol Rep. 2013;15(9):344.
49. Leplege A, Hunt S. The problem of quality of life in medicine.
JAMA. 1997;278(1):47–50.
50. Netuveli G, et al. Functional limitation in long standing illness
and quality of life: evidence from a national survey. BMJ.
2005;331(7529):1382–3.
51. Felce D, Perry J. Quality of life: its definition and measurement.
Res Dev Disabil. 1995;16(1):51–74.
52. Alonso J, et al. Health-related quality of life associated with
chronic conditions in eight countries: results from the Interna-
tional Quality of Life Assessment (IQOLA) Project. Qual Life
Res. 2004;13(2):283–98.
53. Bonomi AE, Shikiar R, Legro MW. Quality-of-life assessment
in acute, chronic, and cancer pain: a pharmacist’s guide. J Am
Pharm Assoc (Wash). 2000;40(3):402–16.
54. Svedlund J, Sjodin I, Dotevall G. GSRS—a clinical rating scale
for gastrointestinal symptoms in patients with irritable bowel
syndrome and peptic ulcer disease. Dig Dis Sci. 1988;33(2):
129–34.
55. O’Keefe EA, et al. A bowel symptom questionnaire for the
elderly. J Gerontol. 1992;47(4):M116–21.
56. Slappendel R, et al. Validation of the PAC-SYM questionnaire
for opioid-induced constipation in patients with chronic low
back pain. Eur J Pain. 2006;10(3):209–17.
57. Marquis P, et al. Development and validation of the Patient
Assessment of Constipation Quality of Life questionnaire. Scand
J Gastroenterol. 2005;40(5):540–51.
58. Rentz AM, et al. Validation of the Bowel Function Index to
detect clinically meaningful changes in opioid-induced consti-
pation. J Med Econ. 2009;12(4):371–83.
59. Rentz AM, et al. Observational, nonintervention, multicenter
study for validation of the Bowel Function Index for constipa-
tion in European countries. Curr Med Res Opin. 2011;27(1):
35–44.
60. Coffin B, Causse C. Constipation assessment scales in adults: a
literature review including the new Bowel Function Index.
Expert Rev Gastroenterol Hepatol. 2011;5(5):601–13.
61. Ueberall MA, et al. The Bowel Function Index for evaluating
constipation in pain patients: definition of a reference range for a
non-constipated population of pain patients. J Int Med Res.
2011;39(1):41–50.
62. Ducrotte P, Causse C. The Bowel Function Index: a new vali-
dated scale for assessing opioid-induced constipation. Curr Med
Res Opin. 2012;28(3):457–66.
63. Knowles CH, et al. Linear discriminant analysis of symptoms in
patients with chronic constipation: validation of a new scoring
system (KESS). Dis Colon Rectum. 2000;43(10):1419–26.
64. Abramowitz L, et al. Further validation of the psychometric
properties of the Bowel Function Index for evaluating opioid-
induced constipation (OIC). J Med Econ. 2013;16(12):1434–41.
65. Abramowitz L, et al. Prevalence and impact of constipation and
bowel dysfunction induced by strong opioids: a cross-sectional
survey of 520 patients with cancer pain: DYONISOS study.
J Med Econ. 2013;16(12):1423–33.
66. Garratt A, et al. Quality of life measurement: bibliographic
study of patient assessed health outcome measures. BMJ.
2002;324(7351):1417.
67. Ware JE Jr, Sherbourne SD. The MOS 36-item short-form
health survey (SF-36). I. Conceptual framework and item
selection. Med Care. 1992;30(6):473–83.
68. Feeny D. A utility approach to the assessment of health-related
quality of life. Med Care. 2000;38(9 Suppl):2151–4.
69. Torrance GW. Utility approach to measuring health-related
quality of life. J Chronic Dis. 1987;40(6):593–603.
70. Guest JF, Clegg JP, Helter MT. Cost-effectiveness of macrogol
4000 compared to lactulose in the treatment of chronic func-
tional constipation in the UK. Curr Med Res Opin. 2008;24(7):
1841–52.
71. Candrilli SD, Davis KL, Iyer S. Impact of constipation on opioid
use patterns, health care resource utilization, and costs in cancer
patients on opioid therapy. J Pain Palliat Care Pharmacother.
2009;23(3):231–41.
72. Kwong WJ, Diels J, Kavanagh S. Costs of gastrointestinal
events after outpatient opioid treatment for non-cancer pain.
Ann Pharmacother. 2010;44(4):630–40.
73. Iyer S, Davis KL, Candrilli S. Opioid use patterns and health
care resource utilization in patients prescribed opioid therapy
with and without constipation. Manag Care. 2010;19(3):44–51.
74. Hjalte F, et al. The direct and indirect costs of opioid-induced
constipation. J Pain Symptom Manage. 2010;40(5):696–703.
75. Swegle JM, Logemann C. Management of common opioid-
induced adverse effects. Am Fam Physician. 2006;74(8):1347–54.
76. Tamayo AC, Diaz-Zuluaga PA. Management of opioid-induced
bowel dysfunction in cancer patients. Support Care Cancer.
2004;12(9):613–8.
77. Holzer P. Non-analgesic effects of opioids: management of
opioid-induced constipation by peripheral opioid receptor
antagonists: prevention or withdrawal? Curr Pharm Des.
2012;18(37):6010–20.
78. Lanza P, Carey M. The impact of opioid and laxative pre-
scribing habits on constipation in the primary care setting before
and after the introduction of SIGN 44: control of pain in patients
with cancer. Primary Health Care Res Dev. 2006;7:3–9.
79. Camilleri M. Opioid-induced constipation: challenges and
therapeutic opportunities. Am J Gastroenterol. 2011;106(5):
835–42 (quiz 843).
80. Choi YS, Billings JA. Opioid antagonists: a review of their role
in palliative care, focusing on use in opioid-related constipation.
J Pain Symptom Manage. 2002;24(1):71–90.
81. Poulsen JL, et al. Clinical potential of naloxegol in the man-
agement of opioid-induced bowel dysfunction. Clin Exp Gas-
troenterol. 2014;7:345–58.
82. Bader S, Durk T, Becker G. Methylnaltrexone for the treatment
of opioid-induced constipation. Expert Rev Gastroenterol Hep-
atol. 2013;7(1):13–26.
83. Diego L, et al. Novel opioid antagonists for opioid-induced
bowel dysfunction. Expert Opin Investig Drugs. 2011;20(8):
1047–56.
84. Ford AC, Brenner DM, Schoenfeld PS. Efficacy of pharmaco-
logical therapies for the treatment of opioid-induced constipa-
tion: systematic review and meta-analysis. Am J Gastroenterol.
2013;108(10):1566–74 (quiz 1575).
85. Smith K, et al. Naloxone as part of a prolonged release oxy-
codone/naloxone combination reduces oxycodone-induced
slowing of gastrointestinal transit in healthy volunteers. Expert
Opin Investig Drugs. 2011;20(4):427–39.
10 B. Morlion et al.
86. Meissner W, et al. A randomised controlled trial with pro-
longed-release oral oxycodone and naloxone to prevent and
reverse opioid-induced constipation. Eur J Pain. 2009;13(1):
56–64.
87. Lowenstein O, et al. Efficacy and safety of combined prolonged-
release oxycodone and naloxone in the management of moder-
ate/severe chronic non-malignant pain: results of a prospectively
designed pooled analysis of two randomised, double-blind
clinical trials. BMC Clin Pharmacol. 2010;10:12.
88. Sandner-Kiesling A, et al. Long-term efficacy and safety of
combined prolonged-release oxycodone and naloxone in the
management of non-cancer chronic pain. Int J Clin Pract.
2010;64(6):763–74.
89. Dunlop W, et al. Quality of life benefits and cost impact of
prolonged release oxycodone/naloxone versus prolonged release
oxycodone in patients with moderate-to-severe non-malignant
pain and opioid-induced constipation: a UK cost-utility analysis.
J Med Econ. 2012;15(3):564–75.
90. Schutter U, et al. Innovative pain therapy with a fixed combi-
nation of prolonged-release oxycodone/naloxone: a large
observational study under conditions of daily practice. Curr Med
Res Opin. 2010;26(6):1377–87.
91. Rychlik R, Kiencke P, Kresimon J. Healthcare research study
into quality of life and pharmacoeconomic aspects of patients
with chronic back pain being treated with oxycodone/naloxone
or other WHO step opiods. Interim analysis. Article in German.
Gesundh Okon Qual Manag. 2011;16:10–9.
92. Galvez R, Provencio M, Sanz-Ortiz J. Ana´lisis econo´mico de
oxicodona LP/naloxona LP en el manejo del dolor intenso y el
estren˜imiento asociado al tratamiento con opioides en Espan˜a.
Pharmacoecon Span Res Arti. 2012;9(1):21–32.
93. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item
Short-Form Health Survey (SF-36): II. Psychometric and clini-
cal tests of validity in measuring physical and mental health
constructs. Med Care. 1993;31(3):247–63.
94. Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health
Survey: construction of scales and preliminary tests of reliability
and validity. Med Care. 1996;34(3):220–33.
95. Hunt SM, et al. The Nottingham Health Profile: subjective
health status and medical consultations. Soc Sci Med A.
1981;15(3 Pt 1):221–9.
96. The World Health Organization Quality of Life Assessment
(WHOQOL): development and general psychometric properties.
Soc Sci Med. 1998;46(12):1569–85.
97. EuroQol—a new facility for the measurement of health-related
quality of life. Health Policy. 1990;16(3):199–208.
98. Feeny D, et al. Multi-attribute health status classification systems.
Health Utilities Index. Pharmacoeconomics. 1995;7(6):490–502.
99. Schipper H, et al. Measuring the quality of life of cancer
patients: the Functional Living Index-Cancer: development and
validation. J Clin Oncol. 1984;2(5):472–83.
100. Cella DF, et al. The Functional Assessment of Cancer Therapy
scale: development and validation of the general measure. J Clin
Oncol. 1993;11(3):570–9.
101. Aaronson NK, et al. The European Organization for Research
and Treatment of Cancer QLQ-C30: a quality-of-life instrument
for use in international clinical trials in oncology. J Natl Cancer
Inst. 1993;85(5):365–76.
QoL and Healthcare Resource in Patients Receiving Opioids for Chronic Pain 11
